Meabco A/S
- Country
- ๐ฉ๐ฐDenmark
- Ownership
- Private
- Established
- 2001-09-17
- Employees
- 1
- Market Cap
- -
- Website
- http://www.meabco.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)โข Click on a phase to view related trials
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Meabco A/S
- Target Recruit Count
- 18
- Registration Number
- NCT04298333
- Locations
- ๐ฎ๐ฉ
Sanglah University Hospital, Bali, Indonesia
๐จ๐ณNational Taiwan University Hospital, Taipei, Taiwan
๐น๐ญSiriraj Hospital, Mahidol University, Bangkok, Thailand
BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Meabco A/S
- Target Recruit Count
- 29
- Registration Number
- NCT03789019
- Locations
- ๐ท๐บ
Russian Oncological Research Centre n.a. N.N. Blokhin, Russian Academy of Medical Science (RAMS), Moscow, Russian Federation
๐ท๐บSt. Petersburg State Budgetary Health Organization, City Clinical Oncology Dispensary, St Petersburg, Russian Federation
๐ท๐บLeningrad Regional Oncological Centre, St. Petersburg, Russian Federation
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic CancerUnresectable Pancreatic Cancer
- Interventions
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Meabco A/S
- Target Recruit Count
- 16
- Registration Number
- NCT03627390
- Locations
- ๐ช๐ฌ
National Liver Institute, Menoufia University, Cairo, Egypt
BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerStage IV Breast Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Meabco A/S
- Target Recruit Count
- 38
- Registration Number
- NCT03603197
- Locations
- ๐น๐ญ
Udon Thani Cancer Hospital, Udon Thani, Udon Thani Province, Thailand
๐น๐ญSiriraj Hospital, Mahidol University, Bangkok, Thailand
๐น๐ญLampang Cancer Center, Lampang, Thailand
BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerStage IV Breast Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Meabco A/S
- Target Recruit Count
- 36
- Registration Number
- NCT02783794
- Locations
- ๐ท๐บ
Russian Oncological Research Centre n.a. N.N. Blokhin, Russian Academy of Medical Science (RAMS), Moscow, Russian Federation
๐ท๐บState Budgetary Institution of Nizhniy Novgorod Region "Oncology Dispensary of Nizhniy Novgorod" (Branch nr.1), Nizhniy Novgorod, Russian Federation
๐ท๐บSt. Petersburg State Budgetary Health Organization, City Clinical Oncology Dispensary, St Petersburg, Russian Federation
- Prev
- 1
- 2
- Next